ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $311,000 | -31.9% | 7,267 | +1.0% | 0.33% | -36.5% |
| Q2 2019 | $457,000 | -19.0% | 7,193 | -11.6% | 0.51% | -21.3% |
| Q1 2019 | $564,000 | +70.9% | 8,136 | +7.3% | 0.65% | +47.5% |
| Q4 2018 | $330,000 | -22.4% | 7,581 | +36.1% | 0.44% | +5.5% |
| Q3 2018 | $425,000 | +10.4% | 5,570 | +11.2% | 0.42% | +20.7% |
| Q2 2018 | $385,000 | +4.3% | 5,011 | -30.8% | 0.35% | +3.3% |
| Q1 2018 | $369,000 | +20.6% | 7,245 | +26.4% | 0.34% | +46.1% |
| Q4 2017 | $306,000 | – | 5,733 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |